INDBInternet News Database 2.5 Updated 2 min ago · 297 sources Show or hide images Light or dark

US FDA declines to approve Summit lung cancer drug after trial misses key survival goal

Save Like Comments Compare coverage
Image from Reuters

Summary

US FDA declines to approve Summit lung cancer drug after trial misses key survival goal Reuters

Description from Reuters.

Who is covering this

  1. Quartz Leans left Factuality: High US
    FDA declined to approve Summit Therapeutics' lung cancer drug

    The agency said ivonescimab lacks a statistically significant overall survival benefit; Summit said it will continue development

  2. Reuters Center Factuality: Very high GB
    US FDA declines to approve Summit lung cancer drug after trial misses key survival goal - Reuters

    US FDA declines to approve Summit lung cancer drug after trial misses key survival goal Reuters

Comments

Comments need JavaScript.